| Long-Term Extension Study in Participants With Multiple Sclerosis Who Have Completed Study 205MS301 (NCT01064401) to Evaluate the Safety and Efficacy of BIIB019 (NCT01797965) | Biogen | 2013-02-15 |
| Development of a Motivational Intervention to Improve Treatment Adherence in MS (NCT01925690) | University of Missouri, Kansas City | 2013-02-01 |
| Dose-finding Study of MT-1303 (NCT01742052) | Tanabe Pharma Corporation | 2013-01-01 |
| Long-term Effect of Fingolimod on Circulating Immunocompetent Mononuclear Cells in Patients With Multiple Sclerosis (NCT01755871) | Heinrich-Heine University, Duesseldorf | 2013-01-01 |
| Canadian Multicenter Observational Study of Tysabri in Early Relapsing Remitting Multiple Sclerosis Participants (NCT01706107) | Biogen | 2012-11-07 |
| Natalizumab De-escalation to Interferon-beta-1b in Patients With Relapsing-remitting Multiple Sclerosis (NCT01701856) | Claudio Gobbi | 2012-09-01 |
| Evaluation of Patient Retention of Fingolimod vs. Currently Approved Disease Modifying Therapy in Patients With Relapsing Remitting Multiple Sclerosis. (NCT01623596) | Novartis Pharmaceuticals | 2012-06-08 |
| Safety and Efficacy of Natalizumab (BG00002, Tysabri®) in Russian Participants With Relapsing Remitting Multiple Sclerosis (RRMS) (NCT02142205) | Biogen | 2012-05-01 |
| An Efficacy, Safety and Tolerability Study of Glatiramer Acetate (GA) 20 mg/0.5 ml New Formulation Administered Daily by Subcutaneous (SC) Injection in Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS) (NCT01578785) | Teva Branded Pharmaceutical Products R&D, Inc. | 2012-03-01 |
| Disease Control in RRMS Transferring Treatment From Natalizumab to Fingolimod (NCT02277964) | University Hospital, Basel, Switzerland | 2012-03-01 |
| Vitamin D Supplementation in Multiple Sclerosis (NCT01490502) | Johns Hopkins University | 2012-03-01 |
| Observational Study of Tysabri in Early Relapsing-Remitting Multiple Sclerosis in Anti-JC Virus Antibody Negative Participants (NCT01485003) | Biogen | 2012-02-07 |
| A Study of MSDx Complex 1 as a Marker for Therapy Response in Multiple Sclerosis (NCT01541618) | MSDx, Inc. | 2012-01-01 |
| Evaluation of Patient Reported Outcomes in RRMS Patients Candidates for MS Therapy Change and Transitioned to Fingolimod 0.5 mg (EPOC) (NCT01534182) | Novartis Pharmaceuticals | 2012-01-01 |
| Efficacy of Fingolimod in de Novo Patients Versus Fingolimod in Patients Previously Treated With a First Line Disease Modifying Therapy (NCT01498887) | Novartis Pharmaceuticals | 2011-12-24 |
| Ireland Natalizumab (TYSABRI) Observational Program (NCT01943526) | Biogen | 2011-11-30 |
| An Open-Label Immunogenicity and Pharmacokinetics Study of Daclizumab High Yield Process Prefilled Syringe in Relapsing Remitting Multiple Sclerosis (NCT01462318) | Biogen | 2011-11-01 |
| Combination of Antidepressants and Fingolimod Relapsing-remitting Multiple Sclerosis (RRMS) Patients With Depression (NCT01436643) | Novartis Pharmaceuticals | 2011-11-01 |
| Effects of Electromechanical Gait Trainer in Patients With Multiple Sclerosis (NCT01564511) | Universita di Verona | 2011-11-01 |
| Phase 3 Study to Evaluate Efficacy and Safety of NU100 in Patients With Relapsing Remitting Multiple Sclerosis (RRMS) (NCT01464905) | Nuron Biotech Inc. | 2011-10-01 |
| Estriol Treatment in Multiple Sclerosis (MS): Effect on Cognition (NCT01466114) | University of California, Los Angeles | 2011-10-01 |
| Glatiramer Acetate for Multiple Sclerosis With Autoimmune Comorbidities (NCT01456416) | University of Southern California | 2011-09-01 |
| Safety, Tolerability And Mechanism Of Action Of Boswellic Acids (BA) In Multiple Sclerosis (SABA) (NCT01450124) | Universitätsklinikum Hamburg-Eppendorf | 2011-09-01 |
| A Phase IIa Study of NT-KO-003 for Multiple Sclerosis (NCT01428726) | Neurotec Pharma | 2011-06-01 |
| Patients With Relapse Remitting Multiple Sclerosis (RRMS): Candidates for MS Therapy Change (NCT01317004) | Novartis Pharmaceuticals | 2011-05-01 |
| Impact of Vitamin A on Gene Expression, in Multiple Sclerosis Patient (NCT01407211) | Tehran University of Medical Sciences | 2011-04-01 |
| Advanced MRI Measures of Repair in Alemtuzumab Treated Patients (NCT01307332) | University of British Columbia | 2011-03-01 |
| Autologous Mesenchymal Stem Cell (MSC) Transplantation in MS (NCT00813969) | The Cleveland Clinic | 2011-03-01 |
| Biomarker Study After Initiation of Treatment With Fingolimod (FTY720) in Patients With Relapsing-remitting Multiple Sclerosis (NCT01310166) | Novartis Pharmaceuticals | 2011-02-01 |
| Supplementation of VigantOL® Oil Versus Placebo as Add-on in Patients With Relapsing Remitting Multiple Sclerosis Receiving Rebif® Treatment (NCT01285401) | Merck KGaA, Darmstadt, Germany | 2011-02-01 |
| High Dose Cyclophosphamide Followed by Glatiramer Acetate in the Treatment of Relapsing Remitting Multiple Sclerosis (NCT00939549) | Johns Hopkins University | 2010-11-01 |
| Safety Study of BIIB033 in Subjects With Multiple Sclerosis (NCT01244139) | Biogen | 2010-10-01 |
| Extension Study to Evaluate Safety and Efficacy of Natalizumab in Japanese Participants With Relapsing-Remitting Multiple Sclerosis (NCT01416155) | Biogen | 2010-10-01 |
| Long-term Safety, Tolerability and Efficacy of BAF312 Given Orally in Patients With Relapsing-remitting Multiple Sclerosis (NCT01185821) | Novartis Pharmaceuticals | 2010-08-30 |
| Using Optical Coherence Tomography (OCT) to Evaluate the Efficacy and Safety of PEGylated Interferon Beta-1a (BIIB017) in Patients With Relapsing Multiple Sclerosis (NCT01337427) | Johns Hopkins University | 2010-08-01 |
| A Study in Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS) to Assess the Efficacy, Safety and Tolerability of Glatiramer Acetate (GA) Injection 40 mg Administered Three Times a Week Compared to Placebo (NCT01067521) | Teva Branded Pharmaceutical Products R&D, Inc. | 2010-06-22 |
| Natalizumab De-escalation With Interferon Beta-1b (NCT01144052) | Claudio Gobbi | 2010-06-01 |
| BG00012 Phase 2 Combination Study in Participants With Multiple Sclerosis (NCT01156311) | Biogen | 2010-06-01 |
| Efficacy of Fish Oil in Multiple Sclerosis (NCT01842191) | Coordinación de Investigación en Salud, Mexico | 2010-05-01 |
| Efficacy and Safety of BIIB019 (Daclizumab High Yield Process) Versus Interferon β 1a in Participants With Relapsing-Remitting Multiple Sclerosis (NCT01064401) | Biogen | 2010-05-01 |
| Safety and Efficacy Extension Study of Daclizumab High Yield Process (DAC HYP) (BIIB019) in Participants Who Have Completed Study 205MS202 (NCT00870740) to Treat Relapsing Remitting Multiple Sclerosis (NCT01051349) | Biogen | 2010-03-31 |
| Study Evaluating Rebif, Copaxone, and Tysabri for Active Multiple Sclerosis (NCT01058005) | Biogen | 2010-03-01 |
| ATX-MS-1467 in Patients With Relapsing Forms of Multiple Sclerosis (NCT01097668) | Apitope Technology (Bristol) Ltd. | 2010-03-01 |
| Treatment Interruption of Natalizumab (NCT01071083) | Biogen | 2010-03-01 |
| Impact of Vitamin A on RAR Gene Expression in Multiple Sclerosis (NCT01705457) | Tehran University of Medical Sciences | 2010-02-01 |
| Impact of Vitamin A on Multiple Sclerosis (MS) (NCT01417273) | Tehran University of Medical Sciences | 2010-02-01 |
| Patient Research Cohort: Rapidly Evolving Multiple Sclerosis (NCT01044576) | Imperial College London | 2010-01-01 |
| Sensori-motor Integration Training in Multiple Sclerosis (NCT01040117) | Universita di Verona | 2009-12-01 |
| POC-MD MRI-based Trial in Relapsing-remitting Multiple Scler (NCT01051817) | Novartis Pharmaceuticals | 2009-12-01 |
| A Study of Orally Administered BGC20-0134 (Structured Lipid) in Patients With Relapsing Remitting Multiple Sclerosis (RRMS) (NCT01037907) | Boston Scientific Corporation | 2009-11-01 |
| Impact of Vitamin A Supplementation on Immune System in Multiple Sclerosis Patients (NCT01225289) | Tehran University of Medical Sciences | 2009-10-01 |
| Safety of New Formulation of Glatiramer Acetate (NCT00947752) | Teva Branded Pharmaceutical Products R&D, Inc. | 2009-07-01 |
| The Neuroprotective Effect of Lamotrigine and Interferon Beta 1a in Patients With Relapsing-Remitting Multiple Sclerosis (NCT00917839) | Cantonal Hospital of St. Gallen | 2009-06-01 |
| Injection Management With Betaferon: Influence on Adherence, Patients Satisfaction and Health Related Outcomes (BETAPATH) (NCT00902135) | Bayer | 2009-05-01 |
| A Study of Participants With Relapsing-Remitting Multiple Sclerosis (RRMS) (NCT00882999) | Eli Lilly and Company | 2009-04-01 |
| Safety, Tolerability, Efficacy and Optimal Dose Finding Study of BAF312 in Patients With Relapsing-remitting Multiple Sclerosis (NCT00879658) | Novartis Pharmaceuticals | 2009-03-30 |
| Effects of Tysabri (BG00002) Over 12 Months on MS Related Fatigue in Participants With RRMS (NCT00884481) | Biogen | 2009-03-23 |
| A Proof of Concept Study to Evaluate the Effectiveness of Tysabri in Relapsing Remitting Multiple Sclerosis (RRMS) Patient Bladder Function (NCT00818038) | Biogen | 2009-03-01 |
| Comparison of Campath and Rebif Treatment on Cognition in Multiple Sclerosis (MS) (NCT00914758) | Washington Neuropsychology Research Group | 2009-03-01 |
| A 24-Hour Pharmacokinetic Determination of BG00012 After Single-Day Oral Administration in Subjects With MS (NCT00837785) | Biogen | 2009-02-28 |
| BG00012 Monotherapy Safety and Efficacy Extension Study in Multiple Sclerosis (MS) (NCT00835770) | Biogen | 2009-02-03 |
| Safety and Efficacy Extension Study of Daclizumab High Yield Process (DAC HYP) in Participants With Multiple Sclerosis Who Have Completed Study 205MS201 (NCT00390221) to Treat Relapsing-Remitting Multiple Sclerosis (NCT00870740) | Biogen | 2009-02-01 |
| A Proof-of-Concept Study to Correlate Retinal Nerve Fiber Layer Changes in Patients With Multiple Sclerosis Treated With Natalizumab or Interferon Beta 1-a (NCT00771043) | Biogen | 2008-11-01 |
| Exploratory Study on the Timing of Multiple Sclerosis (MS) Symptoms (NCT00919217) | University of Louisville | 2008-08-01 |
| Helminth-induced Immunomodulation Therapy (HINT) in Relapsing-remitting Multiple Sclerosis (NCT00645749) | University of Wisconsin, Madison | 2008-07-01 |
| Simvastatin as an add-on Treatment to Copaxone for the Treatment of Relapsing Multiple Sclerosis (NCT00429442) | Anna Tsakiri | 2008-03-01 |
| CLARITY Extension Study (NCT00641537) | EMD Serono Research & Development Institute, Inc. | 2008-02-29 |
| fMRI Study of Treatment Recommendations Comparing Recently Diagnosed Multiple Sclerosis (MS) Patients to Controls (NCT00391352) | Waukesha Memorial Hospital | 2008-02-01 |
| Safety and Efficacy Study of Daclizumab High Yield Process (DAC HYP) to Treat Relapsing-Remitting Multiple Sclerosis (NCT00390221) | Biogen | 2008-02-01 |
| Flupirtine as Oral Treatment in Multiple Sclerosis (NCT00623415) | Charite University, Berlin, Germany | 2007-12-01 |
| Safety Study of Natalizumab to Treat Multiple Sclerosis (MS) (NCT00559702) | Biogen | 2007-10-01 |
| Sunphenon Epigallocatechin-gallate (EGCg) in Relapsing-remitting Multiple Sclerosis (SuniMS Study) (NCT00525668) | Charite University, Berlin, Germany | 2007-09-01 |
| Tysabri Observational Program (NCT00493298) | Biogen | 2007-06-29 |
| How Side Effects of Avonex Are Affected by Gradually Increasing to Full Dose vs Starting at Full Dose (NCT00574041) | Biogen | 2007-06-01 |
| Efficacy and Safety Study of Oral BG00012 With Active Reference in Relapsing-Remitting Multiple Sclerosis (NCT00451451) | Biogen | 2007-06-01 |
| A Combination Trial of Copaxone Plus Estriol in Relapsing Remitting Multiple Sclerosis (RRMS) (NCT00451204) | University of California, Los Angeles | 2007-03-01 |
| Efficacy, Safety and Tolerability of Atorvastatin 40 mg in Patients With Relapsing-remitting Multiple Sclerosis Treated With Interferon-beta-1b (NCT01111656) | Insel Gruppe AG, University Hospital Bern | 2007-03-01 |
| Efficacy and Safety of Oral BG00012 in Relapsing-Remitting Multiple Sclerosis (NCT00420212) | Biogen | 2007-01-01 |
| Eszopiclone for Improving Sleep in Multiple Sclerosis (MS) (NCT00594087) | University of Vermont | 2006-12-01 |
| A Study for Patients With Relapsing Remitting Multiple Sclerosis (NCT00869986) | Eli Lilly and Company | 2006-11-01 |
| An fMRI Study of Treatment Optimization Comparing Two Disease Modifying Therapies Used to Treat Relapsing Remitting Multiple Sclerosis (NCT00398528) | Neurognostics | 2006-09-01 |
| Clinical Trial Comparing Treatment of Relapsing-Remitting Multiple Sclerosis (RR-MS) With Two Doses of Glatiramer Acetate (GA). (NCT00337779) | Teva Branded Pharmaceutical Products R&D, Inc. | 2006-08-01 |
| High-Dose Immunosuppression and Autologous Transplantation for Multiple Sclerosis (HALT MS) Study (NCT00288626) | National Institute of Allergy and Infectious Diseases (NIAID) | 2006-07-01 |
| Autologous T Cell Vaccine (TCV) for Multiple Sclerosis (NCT00245622) | Opexa Therapeutics, Inc. | 2006-05-01 |
| GER-009-06-AVX Early Therapy in Multiple Sclerosis (NCT00492570) | Biogen | 2006-04-01 |
| Natalizumab (Tysabri) Re-Initiation of Dosing (NCT00297232) | Biogen | 2006-03-01 |
| Efficacy and Safety of Fingolimod in Patients With Relapsing-remitting Multiple Sclerosis (NCT00289978) | Novartis | 2006-01-01 |
| An Extension Study of LAQ/5062 Exploring the Long Term Safety, Tolerability and Clinical Effect Parameters During the Disease (NCT00745615) | Teva Pharmaceutical Industries, Ltd. | 2005-12-07 |
| A Safety Study of Combination Treatment With Avonex and Zocor in Relapsing Remitting Multiple Sclerosis (NCT00242268) | Alabama Neurology Associates, PC | 2005-10-01 |
| A Study to Evaluate the Long Term Safety and Effectiveness of Novantrone Therapy Followed by Copaxone Treatment for Multiple Sclerosis (NCT00203086) | Teva Branded Pharmaceutical Products R&D, Inc. | 2005-10-01 |
| An Observational Study of Multiple Sclerosis (MS) Patients Starting or Restarting Baseline Treatment With Interferon Beta 1a After the Use of Escalation Treatment With Mitoxantrone (NCT01142518) | Merck KGaA, Darmstadt, Germany | 2005-07-01 |
| An Observational Study Evaluating Therapy Optimisation Using High-frequency and High-dosage Administration of Interferon-beta (Rebif®) in Multiple Sclerosis (MS) Patients (NCT01142453) | Merck KGaA, Darmstadt, Germany | 2005-05-01 |
| A Study to Evaluate the Effectiveness, Tolerability and Safety of Laquinimod (NCT00349193) | Teva Branded Pharmaceutical Products R&D, Inc. | 2005-03-01 |
| A Postmarketing Surveillance (PMS) Study to Evaluate the Extent to Which Patient Compliance is Influenced by Use of a Variable Titration Regimen at the Start of Treatment of Relapsing Multiple Sclerosis (MS) With Interferon Beta 1a (Rebif®) (NCT01142492) | Merck KGaA, Darmstadt, Germany | 2005-01-01 |
| Assessment Study of Steroid Effect in Relapsing Multiple Sclerosis Subjects Treated With Glatiramer Acetate (NCT00203047) | Teva Branded Pharmaceutical Products R&D, Inc. | 2005-01-01 |
| Combination Therapy in Patients With Relapsing-Remitting Multiple Sclerosis (MS)CombiRx (NCT00211887) | Fred Lublin | 2005-01-01 |
| Omega-3 Fatty Acid Treatment in Multiple Sclerosis (NCT00360906) | Haukeland University Hospital | 2004-12-01 |
| Safety and Efficacy of Pravastatin in Relapsing-remitting Multiple Sclerosis (NCT00200655) | Nantes University Hospital | 2004-12-01 |
| Implementation Study of Treatment Optimization Recommendations on Relapsing-Remitting Multiple Sclerosis (RR MS) Subjects (NCT00101959) | EMD Serono | 2004-11-01 |
| A fMRI(Functional Magnetic Resonance Imaging) Research Study to Learn More About Multiple Sclerosis and Individuals Potentially Experiencing Memory Difficulties (NCT00315367) | Neurognostics | 2004-09-01 |